Argenx Se (ARGX) Income from Discontinued Operations (2018 - 2025)
Argenx Se's (ARGX) quarterly Income from Discontinued Operations came in at 129656000.0 in Q4 2025, down 81.15% YoY from 687652000.0 in Q4 2024, and up 210.22% on a QoQ basis from 41795000.0 in Q3 2025.
Argenx Se (ARGX) Income from Discontinued Operations (2018 - 2025) Analysis & Trends
Argenx Se (ARGX) has 6 years of Income from Discontinued Operations data on file, last reported at 129656000.0 in Q4 2025.
- Quarterly Income from Discontinued Operations fell 81.15% year-over-year to 129656000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 97018000.0 (down 87.03% YoY) and the FY2025 annual result came in at 13428000.0, down 98.2% from the prior year.
- Income from Discontinued Operations climbed to 129656000.0 in Q4 2025, from 41795000.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of 687652000.0 in Q4 2024 to a low of 41541000.0 in Q2 2025.
- A 5-year average of 49102944.44 and a median of 6522000.0 in 2021 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2023 — Income from Discontinued Operations slumped 1547.39% — and 2024, when it jumped 1909.9%.
- Tracing ARGX's Income from Discontinued Operations over 5 years: stood at 7062000.0 in 2021, then tumbled by 62.83% to 2625000.0 in 2022, then tumbled by 1547.39% to 37994000.0 in 2023, then jumped by 1909.9% to 687652000.0 in 2024, then sank by 81.15% to 129656000.0 in 2025.
- The last three Income from Discontinued Operations figures came in at 129656000.0 (Q4 2025), 41795000.0 (Q3 2025), and 41541000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 129.66 Mn |
| Sep 30, 2025 | 41.80 Mn |
| Jun 30, 2025 | -41.54 Mn |
| Mar 31, 2025 | -32.89 Mn |
| Dec 31, 2024 | 687.65 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 44.07 Mn |
| Mar 31, 2024 | 12.75 Mn |
| Dec 31, 2023 | -37.99 Mn |
| Sep 30, 2023 | 10.64 Mn |
| Jun 30, 2023 | -10.51 Mn |
| Mar 31, 2023 | 47.31 Mn |
| Dec 31, 2022 | 2.63 Mn |
| Sep 30, 2022 | 5.98 Mn |
| Jun 30, 2022 | 8.23 Mn |
| Mar 31, 2022 | 2.89 Mn |
| Dec 31, 2021 | 7.06 Mn |
| Sep 30, 2021 | 2.75 Mn |
| Sep 30, 2018 | 1,163.13 |